Hard contraindication
Medication interactions
HIgh-caution populations
Who Should Avoid Microdosing Psilocybin: Full Contraindications Guide
A thorough, honest account of who should not microdose, who should proceed only with professional guidance, and how to evaluate your own risk profile — covering psychiatric history, medication interactions, age, and physical health conditions.
This page is for educational and harm reduction purposes only — not medical advice. Psilocybin is a controlled substance in most jurisdictions. If you have a medical condition or take medications, consult a qualified healthcare provider before making any decisions about microdosing.
Most harm reduction content about microdosing spends the majority of its space on benefits and protocols, and addresses contraindications in a brief paragraph at the end. This page inverts that. Understanding who should not microdose — and why — is the most consequential safety information in this entire guide series. Read it fully before making any decision.
The Three Categories: Hard Stop, Professional Guidance Required, and High Caution
Contraindications for microdosing fall into three distinct categories that warrant different responses. Understanding which category applies to you determines whether proceeding is appropriate at all, and under what conditions.
🚫
hard contraindications
-
Personal history of psychosis or schizophrenia
-
Family history of psychosis or schizophrenia
-
Bipolar disorder type I
-
Currently taking MAOIs or lithium
-
Active suicidal ideation
-
Pregnancy or breastfeeding
⚠️
Professional guidance required
-
Currently taking SSRIs or SNRIs
-
Bipolar disorder type II
-
Severe or unmanaged anxiety disorder
-
History of trauma without active support
-
Cardiac valve conditions
-
Under 25 years old
✓
Proceed with additional care
-
Dose days feel indistinguishable from off days for two or more consecutive dose days
-
You feel the urge to increase your dose to "feel something"
-
Effects that were clear in weeks 1–2 are absent in weeks 4–5
-
No difference between dose and off day scores in your journal
WHY THIS PAGE EXISTS |
Psilocybin has a favorable physiological safety profile — no organ toxicity, no physical dependence, no documented fatal overdose. But physiological safety and psychological safety are different things entirely. The serious risks of microdosing are almost entirely in the psychological domain, and they are concentrated in specific, identifiable populations. This guide exists to make those populations clearly visible so that people in them can make genuinely informed decisions rather than proceeding on the basis of incomplete information.
Hard Contraindications: Do Not Proceed
Hard contraindications are conditions or circumstances under which microdosing should not be undertaken regardless of dose level, protocol choice, or supporting structure. These are not guidelines — they are limits based on documented risk of serious harm. If any of the following applies to you, the appropriate response is to stop here.
Personal or family history of psychosis or schizophrenia
Includes schizoaffective disorder, schizotypal personality disorder, and any episode of psychosis regardless of cause or duration
This is the clearest and most serious contraindication for psilocybin at any dose. Psilocybin can precipitate psychotic episodes in individuals with genetic predisposition — including people who have never previously shown psychotic symptoms. The risk is not hypothetical; there are documented cases of psychotic breaks triggered by psychedelic use in predisposed individuals.
Critically, this applies to family history as well as personal history. A first-degree relative (parent or sibling) with schizophrenia or psychosis significantly elevates your genetic risk even if you have never experienced psychotic symptoms yourself. This risk applies at sub-perceptual microdose levels — the predisposition threshold is lower than the perceptual threshold for most people.
Bipolar disorder type I
Includes any confirmed diagnosis of bipolar I, regardless of current mood state or medication status
Psilocybin can trigger manic or hypomanic episodes in people with bipolar I, even when currently stable and well-managed with medication. The serotonergic activation that makes psilocybin therapeutically interesting for depression is the same mechanism that can destabilise mood in bipolar I. Even if you have been euthymic for years and are considering microdosing because your current medication is inadequate, this is a contraindication — not a caution.
Bipolar II is a different and more nuanced situation — see the high-caution section below.
Currently taking MAOIs
Monoamine oxidase inhibitors — including phenelzine, tranylcypromine, selegiline, isocarboxazid, and some Parkinson's meds
MAOIs combined with psilocybin create a significant risk of serotonin syndrome — a potentially life-threatening condition involving excessive serotonergic activity. The interaction is pharmacologically dangerous at any dose. There is no safe threshold for combining these substances. If you take an MAOI for any reason — depression, anxiety, Parkinson's disease, or otherwise — microdosing psilocybin is contraindicated without exception.
Currently taking lithium
Lithium carbonate or lithium citrate at any prescribed dose
Multiple case reports document seizures in individuals who combined psilocybin with lithium. The mechanism is not fully characterised, but the pattern across case reports is clear enough to constitute a hard contraindication. If you take lithium for bipolar disorder, mood stabilisation, or any other reason, do not combine it with psilocybin at any dose.
If you take lithium and are curious about psychedelic-adjacent approaches to your condition, the appropriate pathway is clinical psilocybin therapy under close medical supervision — not self-administered microdosing.
Active suicidal ideation
Any current thoughts of suicide or self-harm, regardless of perceived severity or intent
Self-administered microdosing is not appropriate for anyone in active psychological crisis. Psilocybin can amplify and accelerate emotional states unpredictably — including negative ones. The fact that full-dose psilocybin therapy shows promise for treatment-resistant depression does not mean self-administered microdosing is appropriate in acute crisis. These are fundamentally different contexts.
If you are experiencing suicidal thoughts, please contact the 988 Suicide and Crisis Lifeline (call or text 988), go to your nearest emergency room, or contact your mental health provider immediately. Microdosing is not a substitute for crisis care.
Pregnancy or breastfeeding
Any stage of pregnancy, and the full duration of breastfeeding
No safety data exists for psilocybin during pregnancy or breastfeeding, and the precautionary principle applies absolutely. Psilocin crosses the blood-brain barrier and is likely to cross the placental barrier. The potential for harm to fetal neurodevelopment — during a period of rapid serotonergic system development — is a risk that cannot be quantified but also cannot be dismissed. This is a hard limit with no exceptions.
Medication Interactions: Full Reference
Beyond the hard contraindications above, a range of medications interact with psilocybin in ways that range from dangerous to functionally significant. If you take any psychiatric or neurological medication, verify it against this table before proceeding — and discuss with your prescriber.
Medication Class | Description | Risk Level | Mechanism | Guidance |
|---|---|---|---|---|
MAOIs | Phenelzine, tranylcypromine, selegiline | Avoid — hard stop | Serotonin syndrome risk; dramatically potentiates psilocybin | Do not combine under any circumstances |
Lithium | Lithobid, Eskalith, lithium citrate | Avoid — hard stop | Seizure risk documented in multiple case reports | Do not combine under any circumstances |
SSRIs | Lexapro, Zoloft, Prozac, Paxil, Celexa | Caution | 5-HT2A downregulation reduces psilocybin effect significantly | May largely negate microdosing benefit. Do not stop without medical supervision. |
SNRIs | Effexor, Cymbalta, Pristiq | Caution | Similar to SSRIs; dual reuptake inhibition adds complexity | Discuss with prescriber. Likely reduces effects; interaction data limited. |
Tricyclic antidepressants | Amitriptyline, nortriptyline, clomipramine | Caution | Anticholinergic and serotonergic overlap; unpredictable interaction | Medical guidance required before proceeding |
Antipsychotics | Quetiapine, risperidone, aripiprazole, olanzapine | Caution | 5-HT2A antagonism may blunt effects or interact unpredictably | Underlying diagnosis likely also a contraindication; medical guidance essential |
Mood stabilisers (non-lithium) | Lamotrigine, valproate, carbamazepine | Caution | Variable interaction profiles; lamotrigine may reduce psilocybin effects | Discuss with prescriber; do not adjust without medical guidance |
Stimulants (ADHD) | Adderall, Vyvanse, Ritalin, Concerta | Unknown | Different neurotransmitter systems; community reports mixed | No hard contraindication; proceed with caution and medical awareness |
Benzodiazepines | Xanax, Valium, Klonopin, Ativan | Low concern | GABAergic; will reduce psilocybin effects (used in trip termination) | Not a safety risk; will blunt microdosing effects. Watch for dependency. |
Beta blocker | Propranolol, metoprolol, atenolol | Low concern | May modulate cardiovascular effects mildly | Likely benign; inform prescriber |
Cannabis/THC | All THC-containing products | Caution | Synergistic psychoactive effects; can amplify anxiety unpredictably | Avoid combining on dose days, especially early cycles |
Note: Another trusted online resource for checking potential psychedelic drug contraindications in advance is the SpiritPharmacist’s Drug Interaction PDF Guide.
DO NOT STOP PSYCHIATRIC MEDICATION TO MICRODOSE |
Discontinuing SSRIs, antipsychotics, mood stabilisers, or any psychiatric medication without medical supervision can cause serious, sometimes dangerous effects including rebound depression, anxiety, withdrawal symptoms, and psychiatric destabilisation. If you want to explore microdosing and are currently medicated, the correct path is a conversation with a psychedelic-informed prescriber — not unilateral medication cessation.
High-Caution Populations: Proceed Only With Professional Guidance
The following conditions do not constitute absolute contraindications — people in these groups can and do microdose, and some report meaningful benefit. However, the risk profile is elevated enough that proceeding without professional support is not responsible harm reduction. These populations require more careful preparation, closer monitoring, and ideally active collaboration with a healthcare provider.
Condition / Situation | Why caution is required | Minimum safeguards before proceeding |
|---|---|---|
Bipolar disorder type II | Risk of triggering hypomania; mood destabilisation possible even without full manic episodes | Psychiatrist aware and monitoring; stable for minimum 12 months; not on lithium |
Currently on SSRIs or SNRIs | Significant blunting of effect likely; interaction profile not fully characterised; do not stop meds to microdose | Prescriber informed; medication not adjusted for microdosing; realistic expectations about reduced effect |
Severe anxiety disorder (unmanaged) | Psilocybin can amplify anxiety at any dose; risk of worsening the condition rather than alleviating it | Anxiety being actively treated; therapist involved; start at lowest possible dose with extended calibration phase |
Unprocessed trauma | Psilocybin can surface suppressed material; without therapeutic support this can be destabilising rather than integrative | Active therapeutic relationship; therapist aware of microdosing practice; integration support in place |
History of addiction or substance use disorder | Psilocybin is not physically addictive, but psychological reliance is possible; using to manage emotional pain without therapeutic work is a risk | Current sobriety stable; substance use counsellor or therapist involved; clear therapeutic intention for the practice |
Eating disorder (active or history) | Psilocybin can surface body image material; appetite changes on dose days may conflict with recovery; risk of using microdosing to manage symptoms rather than treat them | Eating disorder specialist aware; not in acute phase; nutritional stability confirmed |
Recent significant loss or acute grief | Psilocybin amplifies emotional states; acute grief under microdosing can feel overwhelming without support structures in place | Grief support in place; first cycle deferred until acute phase has stabilised; therapist or counsellor involved |
THE DIFFERENCE BETWEEN CAUTION AND PROHIBITION |
None of the conditions in this table are absolute disqualifiers. The distinction between this category and the hard contraindications above is that here, risk can be meaningfully managed with appropriate support — it is not irreducible. But "can be managed" requires actual management, not just awareness. Proceeding without the safeguards listed is the same as ignoring the caution.
Age Considerations
Under 25: significant caution
The brain continues active development until the mid-twenties, with the prefrontal cortex — responsible for impulse control, decision-making, and emotional regulation — among the last regions to fully mature. Serotonergic system development is ongoing during this period, and introducing a serotonergic psychedelic during an incomplete developmental window carries theoretical risks to neurodevelopmental outcomes that are not well-characterised but are plausible enough to warrant genuine caution.
This does not mean people under 25 who microdose will inevitably experience harm — the research is insufficient to make confident predictions. It means the precautionary principle applies with significant weight, and the risk-benefit calculation is less favourable than for adults whose neurodevelopment is complete.
Under 18: do not proceed
Microdosing psilocybin is not appropriate for anyone under 18. The neurodevelopmental risks are highest in adolescence, legal frameworks universally prohibit minors from using controlled substances, and the psychological vulnerabilities associated with adolescence — identity formation, emotional volatility, peer influence — compound the risk profile substantially.
Over 65: proceed with additional medical awareness
Older adults are not contraindicated for microdosing, but several factors warrant additional attention. Age-related changes in serotonin receptor density and sensitivity mean dose responses may differ from younger populations. Polypharmacy — the use of multiple medications common in older adults — increases the likelihood of relevant interactions. Cardiovascular considerations become more significant with age. Consulting a physician familiar with your full medication list before proceeding is particularly important for this age group.
ON SELF-REPORTED AGE DEMOGRAPHIC |
Survey data consistently shows that the most active microdosing demographic is 25–45 years old — the age group with the most favourable risk-benefit profile. The under-25 population is significantly over-represented in online communities relative to the caution those communities apply to age as a risk factor. If you are in your late teens or early twenties and reading this, the caution here is genuine and not performative.
Physical Health Conditions
Most physical health conditions are not contraindications for microdosing. The primary physical health concerns are cardiovascular and relate to specific mechanisms of psilocybin's action on receptor systems.
Cardiac valve conditions
Psilocybin has activity at 5-HT2B receptors, which are expressed in cardiac valve tissue. Sustained 5-HT2B agonism is associated with cardiac valvulopathy — the same mechanism that led to withdrawal of certain weight-loss and Parkinson's medications. Whether psilocybin at microdose ranges, taken cyclically over months or years, produces meaningful cardiac valve changes is unknown and undemonstrated. No cases have been documented in microdosers. However, for people with pre-existing cardiac valve conditions, this theoretical risk is elevated enough to warrant a discussion with a cardiologist before proceeding.
Hypertension and cardiovascular disease
Psilocybin produces mild, transient increases in heart rate and blood pressure on dose days. For healthy individuals, these are not clinically significant. For people with uncontrolled hypertension, arrhythmias, heart failure, or recent cardiac events, even mild sympathomimetic effects warrant medical evaluation before starting. This is not a hard contraindication — it is a condition requiring physician awareness and sign-off.
Liver conditions
Psilocybin is metabolised to psilocin primarily in the liver via alkaline phosphatase. Severe hepatic impairment may affect metabolism and effective dose. This is unlikely to be relevant at microdose levels for most people, but individuals with significant liver disease should discuss this with their physician.
Seizure disorders
There is no established mechanism by which psilocybin at microdose levels lowers seizure threshold in healthy individuals. However, the lithium-psilocybin seizure interaction documented in case reports suggests some caution is warranted around any condition or medication combination that already elevates seizure risk. People with epilepsy or seizure disorders should discuss psilocybin use with their neurologist.
Self-Assessment Checklist: Before You Proceed
Work through these questions honestly before making any decision. This checklist does not replace professional consultation — it is a structured starting point for your own evaluation.
1
Do you have a personal history of psychosis, schizophrenia, or bipolar disorder type I?
If yes: Do not proceed. These are hard contraindications with no exceptions at the self-administered level.
2
Does a first-degree family member (parent or sibling) have schizophrenia or a psychotic disorder?
If yes: Do not proceed. Family history alone is a hard contraindication due to genetic predisposition risk.
3
Are you currently taking an MAOI or lithium?
If yes: Do not proceed. Both are hard contraindications with serious interaction risk.
4
Are you pregnant or breastfeeding?
If yes: Do not proceed. No safety data exists; precautionary principle applies absolutely.
5
Are you currently experiencing active suicidal ideation?
If yes: Seek crisis support now. Contact 988, your mental health provider, or go to your nearest emergency room. This is not the right moment for microdosing.
6
Are you under 18?
If yes: Do not proceed. If you are 18–25: Significant caution applies. Consider whether the precautionary argument is compelling in your specific case.
7
Do you take any psychiatric medication not listed in the hard contraindication section?
If yes: Check the interaction table and discuss with your prescriber before proceeding. Do not stop medication without medical guidance.
8
Do you have bipolar II, a severe anxiety disorder, unprocessed trauma, or a history of addiction?
If yes: Professional guidance required. Proceed only with a mental health provider aware of and supportive of the practice.
9
Do you have a cardiac valve condition or uncontrolled cardiovascular disease?
If yes: Medical consultation required. Discuss with a cardiologist before proceeding.
10
Have you answered no or "not applicable" to all of the above?
If yes: You may proceed — with appropriate caution, a calibrated starting dose, a structured protocol, a tracking system, and at least one trusted person who knows what you are doing.
If You Are Unsure: How to Get Informed Support
Many people reading this page will land in genuinely ambiguous territory — a condition that is not a hard contraindication but is not clearly safe either, or a medication whose interaction profile is uncertain. The right response to genuine ambiguity is not to proceed and hope for the best. It is to seek more information from people qualified to provide it.
🩺
Psychedelic-informed physicians
Physicians who are familiar with psychedelic medicine are increasingly accessible via telehealth. They can evaluate your medication list, health history, and risk profile in the context of psilocybin — and give you a genuinely informed yes, no, or not without modification. A single consultation is often sufficient.
🧠
Psychedelic-informed therapists
Therapists with psychedelic training can help evaluate psychological readiness, support the practice if it proceeds, and catch problems that self-monitoring misses. For anyone in the high-caution category, an involved therapist is the most important harm reduction step available.
💊
Your prescribing physician
If you are medicated, your prescriber deserves to know you are considering this. The conversation may be easier than you expect — many physicians are aware of the research landscape. If your prescriber is not supportive, a second opinion from a psychedelic-informed physician is reasonable and accessible.
🔬
Clinical trial participation
For people in the hard-contraindication categories who are genuinely interested in psilocybin's therapeutic potential, the appropriate pathway is clinical trial participation — where the setting, monitoring, and support structures are designed for higher-risk populations. Clinicaltrials.gov lists currently recruiting studies.
THE DISCLOSURE QUESTION |
Many people worry that disclosing psilocybin use to a healthcare provider will have negative consequences — legal, professional, or relational. In most jurisdictions, physicians cannot report psilocybin use to law enforcement. Your medical records are confidential. The risks of not disclosing — being prescribed medications that interact dangerously, missing monitoring that would catch an emerging problem — typically outweigh the risks of disclosure. Honest conversations with providers who are not dismissive of psychedelic medicine are far more accessible now than they were five years ago.
FAQ — Who Should Avoid Microdosing
Q1: Can microdosing cause a psychotic episode?
Yes — in people with a personal or family history of psychosis or schizophrenia. This is the most serious potential adverse outcome of psilocybin use and the clearest hard contraindication. For people without this predisposition, a psychotic episode from microdosing is extremely rare. The risk is not zero for anyone, which is why conservative dosing and honest self-monitoring matter, but it is substantially and specifically elevated in people with genetic vulnerability. Family history alone — even without personal symptoms — is sufficient to constitute a hard contraindication.
Q2: Can I microdose if I have anxiety?
It depends on the severity and how well the anxiety is currently managed. Many people with mild to moderate anxiety report that microdosing reduces their anxiety over time, and there is preliminary evidence supporting this. People with severe or unmanaged anxiety disorders are at meaningful risk of amplification rather than reduction, particularly in early cycles. If you have anxiety, start at the absolute floor of the dose range, have a therapist or support person involved, and monitor carefully using a daily journal. Anxiety that worsens consistently on dose days is a clear signal to reduce the dose or stop entirely.
Q3: Can I microdose while taking antidepressants?
This requires professional guidance rather than a simple yes or no. SSRIs and SNRIs are not hard contraindications, but they significantly blunt psilocybin's effects through 5-HT2A receptor downregulation — meaning microdosing may produce little or no noticeable benefit. MAOIs are a hard contraindication with serious serotonin syndrome risk. Do not stop or taper any antidepressant to microdose without medical supervision — antidepressant discontinuation carries serious and sometimes dangerous effects. Discuss with a psychedelic-informed prescriber who can evaluate your specific medication and full health context before making any changes.
Q4: Is microdosing safe if I have depression?
For many people with mild to moderate depression who are not currently medicated, microdosing with appropriate support structures in place is not contraindicated and may be beneficial. The evidence for mood improvement is the strongest signal in the microdosing literature. For severe depression, treatment-resistant depression, or depression involving suicidal ideation, self-administered microdosing is not appropriate — the emerging clinical psilocybin therapy framework is a far better-suited pathway. Depression in any form should not be approached as a condition that microdosing alone can address without active therapeutic support alongside it.
Q5: Can people under 25 microdose safely?
The neurodevelopmental concern is genuine and not simply a legal formality. The prefrontal cortex and serotonergic systems continue developing until the mid-twenties, and the long-term effects of serotonergic intervention during this developmental window are not well-characterised. This does not mean every young person who microdoses will be harmed — the research is insufficient for confident predictions. It means the precautionary argument is strong, the risk-benefit calculation is less favourable than for fully-developed adults, and caution is genuinely warranted rather than merely procedural. For anyone under 18, this is a hard stop.
Q6: I have bipolar II — can I microdose?
Bipolar II is not a hard contraindication in the way bipolar I is, but it is a significant high-caution condition that requires professional involvement before proceeding. The risk of triggering hypomania is real, and mood destabilisation is possible even without the full manic episodes associated with bipolar I. Some people with bipolar II microdose under psychiatric supervision and report benefit — particularly for the depressive phase. This requires a psychiatrist who is aware of and monitoring the practice, a period of mood stability of at least 12 months, and confirmed absence of lithium in your medication list. Do not proceed without active professional involvement.
Q7: What should I do if I discover a contraindication after already starting?
Stop immediately. If the contraindication is a hard one — psychosis or schizophrenia history, MAOI or lithium use, bipolar I, pregnancy — do not resume. If the contraindication is in the high-caution category — a significant anxiety disorder, bipolar II, a concerning medication interaction — take a full break of at least two to three weeks and seek professional guidance before considering whether to restart, and under what specific conditions. If you are already experiencing adverse effects such as anxiety, emotional instability, or any perceptual disturbances, contact a healthcare provider promptly. You do not need to disclose psilocybin use to access mental health support, though being honest with your provider helps them make better treatment decisions on your behalf.
Continue reading
Explore the other cluster pages in this guide series.
How to start microdosing safely — complete guide →
Risks and side effects — full guide→
Microdosing for depression — evidence and cautions→
Microdosing and ADHD — evidence and cautions→
Finding psychedelic-informed healthcare providers→
Journal guide — tracking your break period→
Medical disclaimer: This guide is for educational and harm reduction purposes only. It does not constitute medical advice. Psilocybin remains a controlled substance in most jurisdictions. Consult a qualified healthcare professional before making any decisions about your health. The authors do not endorse illegal activity of any kind.